炔雌醇环丙孕酮联合坤泰胶囊治疗多囊卵巢综合征的疗效分析

目的 研究炔雌醇环丙孕酮联合坤泰胶囊治疗多囊卵巢综合征(PCOS)的疗效。方法 选取2017年9月—2018年9月在本院接受治疗的84例PCOS患者,按随机数字表法分为对照组和观察组,每组各42例。对照组患者给予炔雌醇环丙孕酮治疗,观察组患者给予坤泰胶囊联合炔雌醇环丙孕酮治疗。比较2组患者黄体生成素(LH)、睾酮(T)、促卵泡激素(FSH)、排卵率、妊娠率;比较2组患者的临床疗效。结果 治疗后,观察组患者LH、T、FSH水平分别为(3.18±1.01)U/L、(0.71±0.22)U/L、(3.78±1.23)mmol/L,分别低于治疗前的(8.10±2.59)U/L、(1.92±0.61)U/L、(7.29±2.38)mmol/L,且分别低于治疗后对照组的(4.17±1.20)U/L、(0.95±0.31)U/L、(5.01±1.64)mmol/L,差异具有统计学意义(t=4.091、4.092、3.888,P均<0.001);随访2年,观察组患者的排卵率、妊娠率分别为95.24%、64.29%,分别高于对照组的71.43%、28.57%,差异具有统计学意义(χ^(2)=8.571、10.769,P均<0.05);观察组患者的临床疗效总有效率为92.86%,高于对照组的64.29%,差异具有统计学意义(χ^(2)=10.182,P<0.05)。结论 与单独使用炔雌醇环丙孕酮相比,坤泰胶囊联合炔雌醇环丙孕酮治疗PCOS能更有效地降低LH、T、FSH水平,提高患者排卵率、妊娠率。

Analysis of therapeutic effect of ethinylestradiol cyproterone combined with Kuntai capsule on polycystic ovary syndrome

Objective To study the therapeutic effect of ethinylestradiol cyproterone combined with Kuntai capsule on polycystic ovary syndrome (PCOS). Methods A total of 84 patients with PCOS who were treated in our hospital from September 2017 to September 2018 were selected and divided into a control group and an experimental group according to the random number table method, with 42 patients in each group. The patients in the control group were treated with ethinylestradiol cyproterone, and the patients in the experimental group were treated with Kuntai capsule combined with ethinylestradiol cyproterone. Luteinizing hormone (LH), testosterone (T), follicle stimulating hormone (FSH), ovulation rate, and pregnancy rate were compared between the two groups. The clinical effects of the two groups were compared. Results After treatment, the levels of LH, T, and FSH in the experimental group were (3.18±1.01) U/L, (0.71±0.22) U/L, and (3.78±1.23) mmol/L respectively, which were lower than those before treatment: (8.10±2.59) U/L, (1.92±0.61) U/L, (7.29±2.38) mmol/L), and lower than those in the control group after treatment: (4.17±1.20) U/L, (0.95±0.31) U/L, (5.01±1.64) mmol / L), and the difference was statistically significant (t=4.091, 4.092, 3.888, all P<0.001). The ovulation rate and pregnancy rate in the experimental group were 95.24% and 64.29% respectively, which were higher than those in the control group (71.43% and 28.57%, respectively), and the differences were statistically significant (χ2=8.571 and 10.769, P<0.05). The total effective rate of the clinical efficacy of the experimental group was 92.86%, higher than that of the control group (64.29%), and the difference was statistically significant (χ2=10.182, P<0.05). Conclusion Compared with ethinylestradiol cyproterone alone, Kuntai capsule combined with ethinylestradiol cyproterone in the treatment of PCOS can more effectively reduce the levels of LH, T, and FSH, and improve the ovulation rate and pregnancy rate.